Lilly Korea announced on the 1st that it had appointed Christopher J. Stokes as its new CEO.
Christopher J. Stokes, the new CEO, is a pharmaceutical and healthcare professional with more than 15 years of extensive work experience in the global pharmaceutical industry. Before he was appointed Representative of Lilly Korea, he served as Representative of Eli Lilly’s South Africa and Sub-Saharan Africa from 2020 until recently.
Christopher J. Stokes, who first joined Eli Lilly’s US headquarters as a public policy analyst in 2008, has been involved in Corporate Affairs, Government Strategy, Pricing, Reimbursement and Access, Strategic Planning, New Product Planning, and Brand Policy Marketing. Brand Payer Marketing) and sales management (Sales Management) have proven excellent performance and positive influence.
In particular, he built leadership by serving as Neurosciences Director of Sales for the West Area, USA and Chief Operations Officer, Eli Lilly, Headquarters.
Christopher J. Stokes, CEO of Lilly Korea, said, “As Lilly Korea’s new CEO, I have a great sense of responsibility and help more Korean patients lead a better life through Lilly’s innovative medicines, and furthermore, have a positive impact on Korean society. We will do our best to deliver,” he said.
Meanwhile, Alberto Riva, the former CEO of Lilly Korea, was newly appointed as the CEO of Eli Lilly Brazil. Since taking office at Lilly Korea in September 2019, Alberto Riva, president of Lilly Korea, has contributed to the growth of Lilly Korea by supplying treatments for various diseases such as anticancer drugs, diabetes, and autoimmune diseases in Korea.
